Case Presentation Prep: Obstructive Jaundice - Mr. Mohd Mujeev, 30M

PART 1 - FIRST PRINCIPLES: What Is Jaundice?

• Senescent RBCs → heme broken down by macrophages → unconjugated (indirect) bilirubin → bound to albumin, transported to liver
• Liver hepatocytes: UDP-glucuronosyltransferase conjugates it → conjugated (direct) bilirubin (water-soluble)
• Excreted into bile → intestine → bacterial action → urobilinogen → most excreted in stool as stercobilin (gives stool its colour), ~20% reabsorbed into portal circulation (enterohepatic circulation) → re-excreted by liver; small amount in urine as urobilin

PART 2 - PATHOPHYSIOLOGY OF THIS PATIENT'S SYMPTOMS

PART 3 - DIFFERENTIAL DIAGNOSIS

In a 30-Year-Old with Recurrent Obstructive Jaundice (Most Likely to Least Likely):

• Most common cause of biliary obstruction overall
• Recurrent, episodic jaundice fits perfectly (stone impacting and passing)
• RUQ pain + jaundice + absence of fever = likely stone without superimposed cholangitis
• Painless jaundice is MORE typical of malignancy; this patient has pain
• 5-10% of patients with cholelithiasis develop CBD stones - Harrison's

• Young patient (30 years) with recurrent jaundice - always think of choledochal cyst
• Classic triad: RUQ pain, jaundice, palpable mass
• May not always have all three findings
• Can present with recurrent attacks, risk of cholangitis and malignancy

• Episodic jaundice in a young person
• Usually associated with IBD (especially ulcerative colitis)
• No IBD history here makes it less likely, but not excluded

• No prior surgery or trauma makes iatrogenic stricture unlikely
• Inflammatory stricture from chronic pancreatitis possible
• Primary chronic pancreatitis possible even in a non-alcoholic (idiopathic)

• Ampullary adenoma, periampullary carcinoma
• Typically painless progressive jaundice; the episodic nature here makes this less likely

• Less likely at age 30, but Courvoisier's law applies:
  • If gallbladder is palpable + painless jaundice → think malignancy over stones (because in chronic cholelithiasis, the GB is fibrotic and cannot distend)
  • In this patient the GB is NOT mentioned as palpable → consistent with stone disease

• Can cause hepatocellular jaundice
• No fever, no vomiting, non-alcoholic - makes viral hepatitis less central
• Must still check LFTs pattern to exclude

• In endemic areas, Ascaris lumbricoides can migrate into CBD causing obstruction
• Should be in differential for young patient, especially in tropical/developing country context

• Unconjugated hyperbilirubinemia, no dark urine (bilirubin not in urine)
• Dark urine here argues against this

PART 4 - INVESTIGATIONS

First Line (Order All Immediately)

• Liver function tests (LFTs): Total bilirubin, direct + indirect bilirubin, ALP, GGT, ALT, AST, albumin - to confirm obstructive pattern (ALP 3-4x elevation seen in up to 75% of cholestasis; direct bilirubin >50% of total bilirubin - Current Surgical Therapy)
• CBC: Leukocytosis would suggest cholangitis; anaemia might suggest haemolysis or malignancy
• Coagulation (PT/INR): Cholestasis impairs fat-soluble vitamin absorption → Vitamin K deficiency → coagulopathy (important pre-procedure)
• Renal function/electrolytes: Hepatorenal considerations
• Serum amylase/lipase: Rule out pancreatitis as cause or complication
• Viral hepatitis serology: HBsAg, Anti-HCV, Anti-HAV IgM, Anti-HEV IgM

• Urine for bile salts and pigments (bilirubinuria = confirms conjugated jaundice)
• Urine urobilinogen (absent in complete obstruction)

"MRCP is the noninvasive test of choice for CBD stones with high sensitivity and specificity; however, it lacks the therapeutic advantage of ERCP." - Current Surgical Therapy 14e

• Very strong predictors (any one = high probability >50%): CBD stone on USG, clinical ascending cholangitis, bilirubin >4 mg/dL
• Strong predictors (both = high probability): Dilated CBD on USG (>6 mm with GB in situ), bilirubin 1.8-4 mg/dL
• Moderate predictors: Abnormal LFTs other than bilirubin, age >55, dilated CBD on cross-sectional imaging

PART 5 - ERCP: INDICATIONS, CONTRAINDICATIONS, PROCEDURE

• Biliary drainage in obstructive jaundice
• CBD stone removal (choledocholithiasis/cholangitis)
• Biliary stenting for strictures and leaks
• Pancreatitis of unknown aetiology
• Biliary or pancreatic duct tissue sampling
• Sphincter of Oddi manometry
• Balloon dilation of papilla or ductal stricture
• Choledochocele involving major papilla
• Sphincterotomy

• Abdominal pain of obscure origin without objective biliary/pancreatic findings
• Suspected gallbladder disease without bile duct disease
• Known pancreatic malignancy unless management will be altered

• Haemodynamically unstable patient
• Relative: Altered anatomy (e.g., Roux-en-Y, Billroth II), severe coagulopathy

• Pregnancy test in women of childbearing age
• CBC + coagulation for active bleeding or anaemia
• Serum chemistry for significant renal/hepatic dysfunction
• Chest X-ray for new respiratory symptoms or decompensated heart failure

• Post-ERCP pancreatitis (most common): ~3-5% overall
• Bleeding: Especially post-sphincterotomy
• Cholangitis/sepsis
• Perforation: Duodenal or biliary (rare)
• Contrast reactions

PART 6 - CHOLANGITIS (KEY COMPLICATION)

This patient has NO fever - so cholangitis is not currently present, but at risk.

• ERCP with biliary decompression is the procedure of choice
• ERCP within 48 hours associated with nearly 2-fold reduction in mortality (Iqbal et al. meta-analysis)
• Delay >72 hours increases composite outcome of death, organ failure, ICU admission - Current Surgical Therapy 14e
• Antibiotics to cover gram-negative enteric organisms (E. coli, Klebsiella) and anaerobes

PART 7 - SURGICAL MANAGEMENT

For This Patient (Likely Choledocholithiasis)

• Endoscopic sphincterotomy opens the sphincter of Oddi
• Balloon catheters and baskets used to sweep stones out
• Stent placement if stones cannot be cleared in one session

• After CBD clearance, cholecystectomy should be done (same admission for biliary pancreatitis; elective for stable patients)
• Prevents recurrent stone formation and complications

Alternative/Backup Options:

PART 8 - SPECIFIC CLINICAL SIGN EXPLANATIONS

PART 9 - APPROACH TO MALIGNANT OBSTRUCTIVE JAUNDICE (Know for Comparison)

• Carcinoma of pancreatic head (most common malignant cause)
• Cholangiocarcinoma (Klatskin tumour at hilum)
• Ampullary carcinoma (best prognosis among periampullary tumours)
• Gallbladder carcinoma

PART 10 - QUICK VIVA-STYLE Q&A SUMMARY

• Current Surgical Therapy 14e (Sameer Khan, Vikesh Singh - Obstructive Jaundice chapter)
• Harrison's Principles of Internal Medicine 22E (2025) - Choledocholithiasis section
• Guyton & Hall Textbook of Medical Physiology - Bilirubin and Jaundice physiology

Why ALP is High in Obstructive Jaundice

1. When bile flow is obstructed, bile acids accumulate upstream in the biliary tree and within hepatocytes
2. Accumulated bile acids act as detergents - they solubilize and release ALP from the canalicular membrane into the bloodstream
3. Simultaneously, bile duct back-pressure and retained bile acids upregulate ALP gene expression - hepatocytes and cholangiocytes actually synthesize MORE ALP
4. This newly synthesized ALP is then regurgitated back into the sinusoids and enters systemic circulation

Result: ALP rises 3-4x in up to 75% of patients with cholestasis. - Current Surgical Therapy 14e

• Bone (osteoblasts)
• Intestinal epithelium
• Placenta
• Kidney

Why GGT is High in Obstructive Jaundice

1. Bile stasis and retained bile acids directly induce GGT gene transcription in hepatocytes and biliary epithelium
2. Bile acids also solubilize GGT from membranes, releasing it into circulation
3. GGT is also highly sensitive to microsomal enzyme induction (alcohol, drugs, phenytoin) - but even without these, cholestasis alone raises it significantly

The Key Clinical Point - Why Both Are Measured Together

• High ALP + High GGT → hepatobiliary origin confirmed (obstructive or cholestatic liver disease)
• High ALP + Normal GGT → look at bone, not liver

One-Line Summary for the Viva:

"In biliary obstruction, retained bile acids solubilize ALP and GGT from canalicular membranes AND upregulate their synthesis - both enzymes are liver/bile-duct specific markers of cholestasis, and a raised GGT confirms that a high ALP is hepatic rather than bony in origin."